Off Label Drug Marketing Fraud Lawsuit and Drug Formulary Fraud Lawsut Information

Drug Formulary Fraud Whistleblower Lawsuit Information, Drug Company Off Label Marketing Fraud Whistleblower Lawsuit Information, Hospital Formulary Drug Fraud Whistleblower Lawsuit Information, Drug Kickback Lasuit Information, and Drug Fraud Marketing Whistleblower Lawsuit Information (Off Label Marketing Fraud, Hospital Formulary Fraud, & Drug Kickback Whistleblower Lawyer) 

Many health care professions have become aware of the strong influence that drug companies now have in determining community standards of care for medication use in patients.  These drug companies push drug samples into many hospitals and often use powerful forms of manipulation including biased research, influencing key medical doctors, and kickbacks to get their drugs placed on hospital formularies. 

Because of the immense power and influence of drug companies, it is becoming common to have drug marketing executives and representative to be able to influence what drugs whole communities.  In many situations the drug companies are more powerful than individual doctors that are forced to follow hospital formularies.  This drug company manipulation of the medical community can be extremely dangerous because it takes important medical decisions out of the hands of individual medical doctors and allows the drug companies to push potentially dangerous drugs for off-label drug uses and in inappropriate situations. 

The drug industry's main goal is to make a profit.  Each drug company is trying to sell as much of their drug as they can regardless of the potential danger to patients or if there are cheaper more effective alternatives available.  If the marketing executives and drug representatives can get their drug placed on a hospital formulary or make it the standard of care in a community, they are able to make lots of money.  Once this is accomplished there are economic incentives to keep expanding the use of the drug to keep expanding off-label uses. 

Recently several large drug companies have been caught fraudulently marketing drugs for off-label purposes.  These drug companies have had to pay Billions of dollars for Medicare Marketing Fraud Off-Label Lawsuits, Medicaid Marketing Fraud Off-Label Lawsuits, and other health care fraud lawsuits.   Despite these large fines, Drug Companies have continued this practice because they are making profits of Hundreds of Billions of Dollars.

"WASHINGTON (AP) -- Federal prosecutors hit Pfizer Inc. with a record-breaking $2.3 billion in fines Wednesday and called the world's largest drug maker a repeating corporate cheat for illegal drug promotions that plied doctors with free golf, massages, and resort junkets." Pfizer to pay record $2.3B penalty over promotions Repeat offender Pfizer paying record $2.3B settlement for illegal drug promotions By Devlin Barrett, Associated Press Writer On Wednesday September 2, 2009, 3:47 pm EDT

The Department of Justice has announced that this penalty is a warning to all drug manufacturers that criminal and civil prosecution of fraudulent drug marketing, fraudulent off label marketing, illegal kickbacks, and other fraud schemes.  They have also announced that there are several new Medicare Fraud and Medicaid Fraud Law Enforcement Teams that are cracking down on Medicare Fraud and Medicaid Fraud Schemes.  These teams will be investigating and prosecuting people that have profited from these scheme and people that knew about the fraudulent scheme, but failed to report them.

Drug Formulary Fraud Whistleblower Lawsuit Information, Drug Company Off Label Marketing Fraud Whistleblower Lawsuit Information, Hospital Formulary Drug Fraud Whistleblower Lawsuit Information, Drug Kickback Lasuit Information, and Drug Fraud Marketing Whistleblower Lawsuit Information (Off Label Marketing Fraud, Hospital Formulary Fraud, & Drug Kickback Whistleblower Lawyer) 

 Medical doctor whistleblowers, physician whistleblowers, neurologist whistleblowers, health care administrator whistleblowers, pharmacist whistleblowers, nurse whistleblowers, or other medical professional  whistleblowers are needed to blow the whistle on Billions of dollars in Off Label Drug  Fraud. and Hospital Formulary Drug Fraud.  If you are aware of hospital formulary drug fraud, fraudulent off label marketing practices, or illegal drug kickbacks, it is extremely important that you step forward and blow the whistleblower on the fraud.  It not only helps prevent the billions of dollars that are stolen each year from Medicare, Medicaid, and taxpayers, but can lead to a large whistleblower reward for properly reporting the fraud and can help prevent potential criminal liability for failing to report drug marketing fraud.

For more information on a Drug Formulary Fraud Whistleblower Lawsuit or Drug Company Off Label Marketing Fraud Whistleblower Lawsuit, please go to the following webpage on Hospital Formulary Drug Fraud Whistleblower Lawsuit Information, Drug Kickback Lawsuit Information, and Drug Fraud Marketing Whistleblower Lawsuit Information.

Securties Fraud Whistleblower Lawsuit Information and Investment Fraud Whistleblower Bounty Actions

Financial Fraud Whistleblower Lawsuits, Securities Fraud Whistleblower Bounty Actions, SEC Whistleblower Incentive Program Claims, Securties Fraud Whistleblower Lawsuit Information, & Dodd-Frank Act Financial Fraud Whistleblower Bounty Actions Provide Economic Incentives for Wall Street Fraud and Financial Fraud Whistleblowers by Texas Securities, Commodity, and Financial Fraud Whistleblower Lawyer Jason Coomer

In the aftermath of unregulated investments that brought the US economy to the brink of collapse and cost investors Trillions of dollars, the federal government is offering financial incentives to securities fraud whistleblowers, commodity fraud whistleblowers, stimulus fraud whistleblowers, and other financial fraud whistleblowers to step up and blow the whistle on investment fraud, Securities and Exchange Commission SEC violations, Commodity Future Trading Commission CFTC violations, derivative fraud, securities fraud and other forms of financial fraud.  Recent legislation not only strengthens existing qui tam and whistleblower protection laws, but also creates new whistleblower bounties that can be collected by whistleblowers that properly report SEC violations, financial fraud, securities fraud, commodities fraud, and stimulus fraud. 

These new whistleblower bounty actions are expected to encourage Wall Street whistleblowers and other investment fraud whistleblowers to come forward and blow the whistle on large scale investment fraud.  By  encouraging investment fraud whistleblowers to expose investment fraud scams and SEC violations committed by the financial industry, Congress is hoping to rebuild confidence in Wall Street and the Financial Sector for investors.

  

Dodd-Frank Wall Street Reform and Consumer Protection Act Created the SEC Incentive Program Allowing New Whistleblower Bounty Provisions that allows Qualified Financial Fraud Whistleblowers, Securities Fraud Whistleblowers, and SEC Violation Whistleblowers to Collect Rewards for SEC Bounty Claims

In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act was signed into law which includes significant new financial fraud bounty whistleblower provisions.  These provisions create economic incentives for SEC violation whistleblowers and other financial fraud whistleblowers with "original information" of SEC violations and financial fraud to blow the on large scale financial fraud and SEC violations.  

These SEC bounty claims must be brought voluntarily under the SEC Bounty Programs by one or more individuals.  The whistleblower or whistleblowers must be a natural person or natural persons, companies or other entity is not eligible to be financial fraud bounty whistleblowers.  Successful SEC violation bounty whistleblowers and financial fraud whistleblowers can collect financial rewards for whistleblower bounty actions that result in the imposition of monetary sanctions of greater than $1 million dollars.  This new financial fraud SEC bounty program is called the "Securities Whistleblower Incentives and Protection". 

Through SEC Whistleblower Bounty Actions the SEC will award between ten percent and thirty percent of the money collected to a qualified whistleblower who voluntarily provides the SEC with original information about a violation of the securities laws that leads to a successful enforcement of an action brought by the SEC that results in monetary sanctions exceeding $1,000,000.00.  

So long as the financial fraud whistleblower or financial fraud whistleblowers base their claims on "original information", any person (not just an employee or insider) may file a SEC financial fraud bounty claim.  Further, if the financial fraud whistleblower is represented by an attorney, the whistleblower may file the financial fraud bounty claim anonymously.  However, before the financial fraud bounty award is paid, the whistleblower's identity shall be revealed to the SEC and SEC shall be provided information about the whistleblower that it requests. 

Securities Fraud Whistleblower Lawsuit Information, SEC Whistleblower Incentive Program Lawsuit Information, Financial Fraud Derivatives Lawsuit Information, Financial Fraud Whistleblower Lawsuit Information, & Financial Fraud Bounty Lawsuit Information

Securities fraud, also known as stock fraud and investment fraud, is the unlawful practice of inducing investors to make investment decisions on the basis of false information, frequently resulting in losses, in violation of the securities laws.  Securities fraud whistleblower lawsuits include deceptive practices in the stock and commodity markets, and occur when investors are enticed to part with their money based on fraudulent misrepresentations.  

Securities fraud whistleblower lawsuits include outright theft from investors and misstatements on a public company's financial reports as well as a wide range of other actions, including insider trading, front running and other illegal acts on the trading floor of a stock or commodity exchange.  Evidence for a securities fraud whistleblower lawsuit may include:

1. False or misleading information on a company's financial statement;
2. False or misleading information on Securities and Exchange Commission (SEC) filings;
3. Lying to corporate auditors;
4. Insider trading;
5. Stock manipulation schemes;
6. Embezzlement by stockbrokers;
7. Manipulation of a security’s price or volume;
8. Fraudulent or unregistered offer or sale of securities, including Ponzi schemes, high yield investment programs or other investment programs;
9. Brokerage Account and Retirement Account Fraud;
10. False or misleading statements about a company;
11. Failure to file required reports with the SEC;
12. Abusive naked short selling;
13. Theft or misappropriation of funds or securities;
14. Fraudulent conduct or other problems associated with municipal securities transactions or public pension plans; and
15. Bribery of foreign officials

Through new legislation the federal government is offering financial incentives to securities fraud whistleblowers and other financial fraud whistleblowers to step up and blow the whistle on properly reporting financial fraud including the above listed forms of securities fraud that lead to SEC violations and fines.  These new whistleblower bounties can be collected by whistleblowers that properly report SEC violations, financial fraud, securities fraud, commodities fraud, and stimulus fraud.

Other forms of SEC Violations including reporting problems with a brokerage or advisory account; fraudulently preventing access to funds or securities; fraudulent order handling, trade execution, or confirmations; fraudulent fees, mark-ups or commissions; and inaccurate or misleading disclosures by financial professionals, may also lead to potential SEC bounties, if the fraudulent acts result in fines of over $1 million and are properly reported.

Securities Fraud Whistleblower Lawsuit Information, SEC Violation Whistleblower Bounty Lawsuit Information, Dodd-Frank Act Financial Fraud Whistleblower Bounty Lawsuit Information, SEC Whistleblower Incentive Program Lawsuit Information, Investment Fraud Whistleblower Lawsuit Information, Securities Fraud Action Information, Commodity Fraud Action Information, and SEC Fraud Whistleblower Lawsuit Information

Financial Fraud Whistleblower Lawsuits, Securities Fraud Whistleblower Lawsuits, Commodity Fraud Whistleblower Lawsuits, Stimulus Fraud Whistleblower Lawsuits, and SEC Violation Whistleblower Lawsuits will become more common with the enactment of laws like the Dodd-Frank Wall Street Reform and Consumer Protection Act that create bounties that can be collected by whistleblowers that properly report SEC violations, financial fraud, securities fraud, commodities fraud, and stimulus fraud that result in monetary sanctions over one million dollars ($1,000,000.00).  The SEC can award the whistleblower up to 30% of the money collected.

By creating whistleblower bounties for investors and people with specific information of financial fraud, it is expected that hard to detect financial fraud including derivative market fraud and investment fraud will be exposed to help regulate the financial market and prevent large investment corporations, banks, hedge funds, and other large corporations from committing financial fraud of billions of dollars.

TARP Fraud Whistleblower Lawsuits, Bail Out Fraud Whistleblower Lawsuits, Financial Fraud Federal False Claims Act Lawsuits, and Stimulus Fraud Qui Tam Whistleblower Lawsuits

Many financial fraud whistleblower lawsuits may include also include elements of stimulus fraud whistleblower qui tam lawsuits or other Federal False Claims Act Lawsuits.  These potential Financial Fraud Actions under the Federal False Claims Act may allow a stimulus fraud whistleblower or other financial fraud whistleblower to potentially collect a large recovery for blowing the whistle on financial fraud. The Troubled Asset Relief Program (TARP) is a $700 Billion Bail Out of the troubled United States Banking and Credit System.  It was designed to unfreeze the credit market and enable the government to purchase residential and commercial mortgage assets, including whole loans and securities.  Unfortunately, after it was announced numerous Corporate interests began scheming on how to get as much of the Bail Out money as possible and use the money not for its intended purpose, but to enrich the corporations, shareholders, and CEOs that were able to get a portion of the money.

When a government imposes a penalty, for the doing or not doing an act, and gives that penalty in part to whistleblowers that will sue for the same, and the other part of the recovery goes to the government, and makes it recoverable by action, such actions are called "qui tam actions", the plaintiff is suing on their own behalf as well for the government and taxpayers. Qui tam provisions of the False Claims Act are based on the theory that one of the least expensive and most effective means of preventing frauds on taxpayers and the government is to make the perpetrators of government fraud liable to actions by private persons acting under the strong stimulus of personal ill will or the hope of gain.

The strong public policy behind creating an economic gain for whistleblowers is that  the government would be significantly less likely to learn of the allegations of fraud, but for persons in certain positions with specialized knowledge of fraud that has been committed. Congress has made it clear that creating this economic incentive is beneficial not only for the government, taxpayers, and the realtor, but is an efficient method of regulating government to prevent fraud and fraudulent schemes.

The central purpose of the qui tam provisions of the False Claims Act is to set up incentives to supplement government regulation and enforcement by encouraging whistleblowers with specialized knowledge of fraud going on in the government to blow the whistle on the crime.

The whistleblower's share of recovery is a maximum of 30 percent and the government's prior knowledge of fraud now does not necessarily bar a whistleblower from collecting lost revenue. If the government takes over the lawsuit, the relator can "continue as a party to the action." The defendant is also required to pay for the relator's attorney fees. The whistleblower is also protected from retaliatory actions by his or her employer. As a result a 1986 amendment to the False Claims Act, qui tam lawsuits have increased dramatically.   Though the amendment was first made for corrupt defense contractors, the amendment has uncovered billions of dollars in health care fraud and will probably apply to fraudulently obtained TARP and Bail Out Funds. 

Securities Fraud Whistleblower Lawsuit Information, SEC Violation Whistleblower Bounty Lawsuit Information, Dodd-Frank Act Financial Fraud Whistleblower Bounty Lawsuit Information, SEC Whistleblower Incentive Program Lawsuit Information, Investment Fraud Whistleblower Lawsuit Information, Securities Fraud Action Information, Commodity Fraud Action Information, and SEC Fraud Whistleblower Lawsuit Information

Through Federal False Claims Act Whistleblower Lawsuits, Qui Tam Lawsuits, and other Government Fraud Lawsuits, billions of dollars have been recovered from fraudulent government contractors and corporations that have committed fraud and stolen large amounts of money from the government and taxpayers.  By seeking the knowledge of sophisticated investors, the SEC is seeking to use their specialized knowledge of securities and investments to expose complicated securities fraud and investment fraud that threaten the public confidence in Wall Street, the financial industry, and investing.

For more information on Investment Fraud Whistleblower Lawsuits including Securities Fraud, Derivatives Fraud, Investment Fraud, and Commodity Fraud follow the following link:  Securities Fraud Whistleblower Bounty Actions and Financial Fraud Whistleblower Lawsuits.

Drug Calibration Fraud Whistleblower Lawsuit Information and Drug Safety Fraud Whistleblower Lawsuit Information

Drug Calibration Fraud Whistleblower Lawsuit Information, Drug Safety Fraud Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Drug Quality Assurance Whistleblower Lawsuit Information  by Drug Safety Fraud Whistleblower, Contaminated Drug Whistleblower, Adulterated Drug Whistleblower, Drug Calibration Fraud Whistleblower, and Pharmaceutical Quality Assurance Whistleblower Lawyer Jason S. Coomer

It is extremely important that pharmaceutical whistleblowers including Drug Quality Fraud Assurance Whistleblowers, Drug Calibration Fraud Whistleblowers, and other Drug Safety Whistleblowers continue to step forward to blow the whistle on adulterated drugs that threaten the health and safety of the people taking medications.  Because of the serious potential danger to the public that can be caused by giving contaminated drugs or improperly calibrated drugs, it is vitally important that whistleblowers help make sure that drugs are properly calibrated and not contaminated.  Further, it is clear that the government will not tolerate any lapses in safety standards from pharmaceutical manufacturers. 

Public policy dictates that whistleblowers and the government work together through large economic incentives and law enforcement to regulate the $800 Billion a year Pharmaceutical Industry to make sure that drug calibration fraud and drug safety fraud are not occurring.  By encouraging pharmaceutical quality assurance, calibration, and safety professionals to step forward and expose fraudulent practices that create adulterated drugs, large awards through the False Claims Act protect the health and lives of children, men, and women.  These awards encourage insiders with special knowledge of drug calibration fraud and drug safety fraud to come forward and blow the whistle on large companies that value profits over drug safety.  

There are several keys to a successful False Claims Act Qui Tam Whistleblower action including 1) obtaining original and specialized information of the fraud, 2) being the first to file regarding the specific fraud, and 3) protecting the whistleblower for retaliation.  Pharmaceutical whistleblowers including Drug Quality Assurance Whistleblowers, Drug Calibration Whistleblowers, and other Drug Safety Whistleblowers that timely and properly blow the whistle on defective and dangerous drugs, may receive a large amount of money for being the first to properly report fraudulent disregard for safety standards and pharmaceutical policies that hide adulterated drugs.   

Pharmaceutical Quality Assurance Whistleblower Lawsuit Information, Drug Safety Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Pharmaceutical Drug Calibration Whistleblower Qui Tam Lawsuit Information by Drug Quality Whistleblower, Contaminated Drug Whistleblower, Adulterated Drug Whistleblower, and Pharmaceutical Quality Assurance Whistleblower Lawyer

 

Health Care Fraud costs United States Tax Payers approximately $90 billion each year through Medicare, Medicaid, and other government health care programs.  This has prompted increased law enforcement of fraud against the FDA, Medicare, and Medicaid.  This increased enforcement by FDA and the offer of large economic incentives to drug calibration fraud whistleblowers and safety fraud whistleblowers is expected expose a large amount of pharmaceutical drug calibration fraud and safety fraud.  

 

It is important for pharmaceutical safety and drug calibration fraud whistleblowers to not delay in coming forward with a False Claim Act Qui Tam Action for many reasons.  First, by coming forward it can expose drug calibration fraud and drug safety fraud that endangers the lives on men, women, and children.  Second, only the first drug calibration fraud whistleblower to file is eligible to be a relator and may make a large recovery for exposing the drug calibration fraud or drug safety fraud.  Third, when the fraudulent  drug calibration scheme is exposed, the people that kept the fraud secret can sometimes be found liable for criminal activity for not exposing the drug safety fraud that was being committed and be held liable for continuing criminal activity.

Drug Calibration Fraud Whistleblower Lawsuit Information, Drug Safety Fraud Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Drug Quality Assurance Whistleblower Lawsuit Information

Drug Calibration Fraud Whistleblower Lawsuits, Drug Safety Fraud Whistleblower Lawsuits, and Contaminated Drug Whistleblower Lawsuits are becoming more common as Pharmaceutical Quality Assurance Managers, Drug Calibration Specialists, and other Drug Safety Whistleblowers are stepping forward to blow the whistle on adulterated drugs, contaminated drugs, and poorly calibrated drugs that threaten the health and lives of children, women, and men that are taking the drugs. 

For more information on Drug Safety Fraud Lawsuits, please go to the following web page on Drug Safety Fraud Whistleblower Lawsuit Information, Adulterated Drug Whistleblower Lawsuit Information, Contaminated Drug Whistleblower Lawsuit Information, and Pharmaceutical Drug Calibration Fraud Whistleblower Lawsuit Information.